Physician profile
Nick Cavros
NPI 1851345326
$1,842.75
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,460 · 2020: $383.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $271.28 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $258.42 | 2019 | |
| Celonova Biosciences, INC. | $149.59 | 2019-2020 | |
| Cardiovascular Systems INC. | $127.73 | 2019 | |
| Janssen Pharmaceuticals, INC | $123.47 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $111.99 | 2019-2020 | |
| Philips North America LLC | $101.29 | 2019 | |
| Pfizer INC. | $99.34 | 2019-2020 | |
| Inari Medical, INC. | $88.85 | 2020 | |
| Ekos Corporation | $81.57 | 2019 | |
| Sanofi-Aventis U.S. LLC | $78.74 | 2019 | |
| Lundbeck LLC | $78.12 | 2019 | |
| Amgen INC. | $75.13 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $66.47 | 2019 | |
| Irhythm Technologies, INC. | $50.93 | 2019-2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.51 | 2019 | |
| Abbott Laboratories | $23.70 | 2019 | |
| Vifor Pharma, INC. | $17.56 | 2019 | |
| Abiomed | $12.06 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nick Cavros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.